The HLA-DQA1*05 genotype does not influence the clinical response to ustekinumab and vedolizumab
Background: the success of strategies with earlier anti-TNF drugs for the treatment of inflammatory bowel disease (IBD) have been shadowed by the development of an ti-drug antibodies that reduce their effectiveness. The HLA DQA1*05 allele has been shown to increase the risk of im munogenicity to ant...
| Autores: | , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2023 |
| País: | España |
| Institución: | Universidad de Sevilla (US) |
| Repositorio: | idUS. Depósito de Investigación de la Universidad de Sevilla |
| OAI Identifier: | oai:idus.us.es:11441/157223 |
| Acceso en línea: | https://hdl.handle.net/11441/157223 https://doi.org/10.17235/reed.2023.9491/2023 |
| Access Level: | acceso abierto |
| Palabra clave: | HLA-DQA1*05 allele Ustekinumab Vedolizum ab Inflammatory bowel disease |
| Sumario: | Background: the success of strategies with earlier anti-TNF drugs for the treatment of inflammatory bowel disease (IBD) have been shadowed by the development of an ti-drug antibodies that reduce their effectiveness. The HLA DQA1*05 allele has been shown to increase the risk of im munogenicity to anti-TNF drugs by approximately two-fold. The negative impact of this allele has not been fully inves tigated for newer biotherapies. Objective: whether the presence of the HLA-DQA1*05 al lele is associated with a reduction of response to usteki numab and vedolizumab was investigated. Material and methods: the impact of HLA-DQA1*05 on dis ease activity in 93 patients with IBD, treated with ustekinum ab (n = 39) or vedolizumab (n = 54) was investigated in a ret rospective cohort study. Treatment response and remission was assessed at 6 and 12 months for ustekinumab, and up to 18 and 24 months for vedolizumab, using Harvey-Bradshaw index (Crohn’s disease) and Mayo score (ulcerative colitis). Results: the HLA-DQA1*05 allele was found in 35.9 % and 38.9 % of patients treated with ustekinumab and vedoli zumab, respectively. Clinical response was not affected by the presence of the HLA-DQA1*05 allele for both treat ment groups. Conclusions: in contrast to anti-TNF drugs, HLA-DQA1*05 presence does not correlate with the decreased response to ustekinumab or vedolizumab. |
|---|